Meridian Bioscience, Inc. (VIVO) Reaches $16.10 52-Week High; PHAROL SGPS SA ORD PORTUGAL (PHRZF) Shorts Increased By 86.09%

January 27, 2018 - By Adrian Mccoy

PHAROL SGPS SA ORD PORTUGAL (OTCMKTS:PHRZF) had an increase of 86.09% in short interest. PHRZF’s SI was 274,300 shares in January as released by FINRA. Its up 86.09% from 147,400 shares previously. It closed at $0.29273 lastly. It is down 0.00% since January 27, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) hit a new 52-week high and has $16.91 target or 5.00% above today’s $16.10 share price. The 7 months bullish chart indicates low risk for the $681.15M company. The 1-year high was reported on Jan, 27 by Barchart.com. If the $16.91 price target is reached, the company will be worth $34.06M more. The stock decreased 0.62% or $0.1 during the last trading session, reaching $16.1. About 351,045 shares traded or 18.03% up from the average. Meridian Bioscience, Inc. (NASDAQ:VIVO) has declined 26.84% since January 27, 2017 and is downtrending. It has underperformed by 43.54% the S&P500.

Pharol, SGPS S.A., through its 27.5% interest in Oi, S.A, provides telecommunication services in Portugal, Brazil, Europe, the United Kingdom, Canada, the United States, and Ireland. The company has market cap of $253.40 million. The firm was formerly known as Portugal Telecom, SGPS, SA and changed its name to Pharol, SGPS S.A. in May 2015. It currently has negative earnings.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $681.15 million. The firm operates through Diagnostics and Life Science divisions. It has a 31.57 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

Investors sentiment increased to 1.37 in 2017 Q3. Its up 0.02, from 1.35 in 2017Q2. It improved, as 12 investors sold Meridian Bioscience, Inc. shares while 42 reduced holdings. 24 funds opened positions while 50 raised stakes. 36.26 million shares or 2.14% more from 35.50 million shares in 2017Q2 were reported. Keybank Association Oh holds 0% or 10,200 shares. 25,585 were reported by Menta Limited Com. Bancshares Of Montreal Can has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). First Manhattan reported 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). Pub Sector Pension Inv Board stated it has 26,771 shares or 0% of all its holdings. 1,982 are owned by Jpmorgan Chase. North Star Invest, a Illinois-based fund reported 53,075 shares. Spark Invest Management Ltd Liability Com invested in 0.13% or 170,800 shares. Ubs Asset Americas accumulated 23,210 shares or 0% of the stock. Connors Investor Services holds 201,852 shares or 0.44% of its portfolio. Blackrock Inc has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Susquehanna Intll Gp Limited Liability Partnership owns 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 29,000 shares. Parkside Natl Bank Tru holds 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 43 shares. Ameritas Ptnrs Inc owns 3,556 shares. Sei reported 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO).

Among 5 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Meridian Bioscience had 13 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Sell” rating by Piper Jaffray on Thursday, July 27. The firm has “Hold” rating given on Thursday, September 10 by Canaccord Genuity. The firm earned “Neutral” rating on Monday, March 21 by Hilliard Lyons. Robert W. Baird maintained the stock with “Hold” rating in Thursday, October 19 report. Piper Jaffray maintained it with “Sell” rating and $10.0 target in Thursday, October 19 report. On Thursday, September 21 the stock rating was maintained by Piper Jaffray with “Sell”. Robert W. Baird maintained Meridian Bioscience, Inc. (NASDAQ:VIVO) on Thursday, January 25 with “Hold” rating. The firm has “Sell” rating by Piper Jaffray given on Thursday, January 25. Hilliard Lyons upgraded the shares of VIVO in report on Monday, March 28 to “Buy” rating. Canaccord Genuity maintained it with “Hold” rating and $16.0 target in Thursday, January 25 report.